Table 2.

Clinical performance of SARS-CoV-2 immunoassays relative to delay with onset of symptoms.

Assay		Euroimmun IgG	Abbott IgG	Wantai Ab	DiaPro IgG confirmation
Platform		ELISA	CLIA (Alinity-i)	ELISA	ELISA
Antigen		S1	N	S (RBD)	S1	S2	N	≥2 Ag
Sensitivity
≥7−13 dps	n/N	4/13	6/13	11/13	7/13	2/13	13/13	8/13
	%	30.8	46.2	84.6	53.8	15.4	100	61.5
	95 % CI	9.1−61.4	19.2−74.9	54.6−98.1	25.1−80.8	1.9−4.5	75.3−100.0	31.6−86.1
≥14 dps	n/N	43/45	43/45	44/45	42/45	28/45	44/45	43/45
	%	95.6	95.6	97.8	93.3	62.2	97.8	95.6
	95 % CI	84.9−99.5	84.9−99.5	88.2−99.9	81.7−98.6	46.5−76.2	88.2−99.9	84.9−99.5
Specificity	n/N	82/89	88/89	89/89	85/89	89/89	75/89	88/89
	%	92.1	98.9	100.0	95.5	100.0	84.3	98.9
	95 % CI	84.5−96.8	93.9−100.0	95.9−100.0	88.9−98.8	95.9−100.0	75.0−91.1	93.9−100.0

dps: days post-onset of symptoms.